$18.86
+0.76(4.20%)
Mkt Cap $3.1B
$6.81
$24.29
52-Week Range
At A Glance
1
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
2
Most recently: Results of Operations and Financial Condition. On March 2, 2026, Dyne Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financi (2026-03-02).
$3.1B
Market Cap
—
Revenue
-$573M
Net Income
Employees192
Fundamentals
How The Business Makes Money
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001818794
ISINUS26818M1080
CUSIP26818M108
Phone781 786 8230
Address1560 Trapelo Road, Waltham, MA, 02451, US
SEC EDGAR